Could This Biosimilar Drug Be Novartis' Next Blockbuster?
Novartis' biosimilar candidate to Eylea has proven just as safe and effective. The medicine could generate $500 million in annual sales for the Swiss drugmaker.
Novartis sues US government over Medicare drug price regulation
Swiss drugmaker Novartis on Friday said it had sued the U.S. government in an attempt to halt the Medicare drug-price negotiation program, which includes its top-selling heart-failure medicine Entr...
Novartis (NVS) Announces Positive Long-Term Data on Leqvio
Novartis (NVS) Leqvio shows consistent efficacy and safety beyond six years in patients with ASCVD.
Novartis' (NVS) Sandoz Gets FDA Nod for Tysabri's Biosimilar
Novartis' (NVS) generic division, Sandoz, wins FDA approval for a biosimilar of the leading MS drug Tysabri.
Novartis (NVS) Plans to Spin-Off Sandoz in Early October
Novartis (NVS) progresses with the proposed spin-off of its Sandoz arm (scheduled for early October) and invites shareholders for a meeting on the same.
Novartis (NVS) Key Drugs and Pipeline Progress Fuel Growth
Novartis (NVS) put up a strong performance year to date based on the solid performance of key drugs and encouraging pipeline progress.
Related Companies